271 related articles for article (PubMed ID: 36452200)
21. Application of a plasmin generation assay to define pharmacodynamic effects of tranexamic acid in women undergoing cesarean delivery.
Miszta A; Ahmadzia HK; Luban NLC; Li S; Guo D; Holle LA; Berger JS; James AH; Gobburu JVS; van den Anker J; de Laat B; Wolberg AS
J Thromb Haemost; 2021 Jan; 19(1):221-232. PubMed ID: 33001565
[TBL] [Abstract][Full Text] [Related]
22. Cell-Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis.
Gould TJ; Vu TT; Stafford AR; Dwivedi DJ; Kim PY; Fox-Robichaud AE; Weitz JI; Liaw PC
Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2544-53. PubMed ID: 26494232
[TBL] [Abstract][Full Text] [Related]
23. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
[TBL] [Abstract][Full Text] [Related]
24. Sex-specific alteration to α2-antiplasmin incorporation in patients with type 2 diabetes.
Bryk AH; Siudut J; Broniatowska E; Bagoly Z; Baráth B; Katona É; Undas A
Thromb Res; 2020 Jan; 185():55-62. PubMed ID: 31770688
[TBL] [Abstract][Full Text] [Related]
25. Analysis of plasmin generation and clot lysis of plasma fibrinogen purified from a heterozygous dysfibrinogenemia, BbetaGly15Cys (Hamamatsu II).
Kamijyo Y; Hirota-Kawadobora M; Yamauchi K; Terasawa F; Honda T; Ikeya M; Okumura N
Blood Coagul Fibrinolysis; 2009 Dec; 20(8):726-32. PubMed ID: 19809304
[TBL] [Abstract][Full Text] [Related]
26. Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk.
Kearney K; Tomlinson D; Smith K; Ajjan R
Cardiovasc Diabetol; 2017 Mar; 16(1):34. PubMed ID: 28279217
[TBL] [Abstract][Full Text] [Related]
27. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
[TBL] [Abstract][Full Text] [Related]
28. Regulation by alpha 2-antiplasmin and fibrin of the activation of plasminogen with recombinant staphylokinase in plasma.
Silence K; Collen D; Lijnen HR
Blood; 1993 Aug; 82(4):1175-83. PubMed ID: 7688990
[TBL] [Abstract][Full Text] [Related]
29. Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics.
Pechlivani N; Kearney KJ; Ajjan RA
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830419
[TBL] [Abstract][Full Text] [Related]
30. Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes.
Agren A; Jörneskog G; Elgue G; Henriksson P; Wallen H; Wiman B
Diabetes Care; 2014 Jul; 37(7):2007-14. PubMed ID: 24760258
[TBL] [Abstract][Full Text] [Related]
31. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
Collen D
J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
[TBL] [Abstract][Full Text] [Related]
32. The role of activated coagulation factor XII in overall clot stability and fibrinolysis.
Konings J; Hoving LR; Ariëns RS; Hethershaw EL; Ninivaggi M; Hardy LJ; de Laat B; Ten Cate H; Philippou H; Govers-Riemslag JW
Thromb Res; 2015 Aug; 136(2):474-80. PubMed ID: 26153047
[TBL] [Abstract][Full Text] [Related]
33. Affimer proteins as a tool to modulate fibrinolysis, stabilize the blood clot, and reduce bleeding complications.
Kearney KJ; Pechlivani N; King R; Tiede C; Phoenix F; Cheah R; Macrae FL; Simmons KJ; Manfield IW; Smith KA; Spurgeon BEJ; Naseem KM; Ariens RAS; McPherson MJ; Tomlinson DC; Ajjan RA
Blood; 2019 Mar; 133(11):1233-1244. PubMed ID: 30545831
[TBL] [Abstract][Full Text] [Related]
34. Incorporation of fragment X into fibrin clots renders them more susceptible to lysis by plasmin.
Schaefer AV; Leslie BA; Rischke JA; Stafford AR; Fredenburgh JC; Weitz JI
Biochemistry; 2006 Apr; 45(13):4257-65. PubMed ID: 16566600
[TBL] [Abstract][Full Text] [Related]
35. The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis.
Hethershaw EL; Cilia La Corte AL; Duval C; Ali M; Grant PJ; Ariëns RA; Philippou H
J Thromb Haemost; 2014 Feb; 12(2):197-205. PubMed ID: 24261582
[TBL] [Abstract][Full Text] [Related]
36. MASP-1 of the complement system alters fibrinolytic behaviour of blood clots.
Jenny L; Noser D; Larsen JB; Dobó J; Gál P; Pál G; Schroeder V
Mol Immunol; 2019 Oct; 114():1-9. PubMed ID: 31325724
[TBL] [Abstract][Full Text] [Related]
37. Termination of bleeding by a specific, anticatalytic antibody against plasmin.
Zhao T; Houng A; Reed GL
J Thromb Haemost; 2019 Sep; 17(9):1461-1469. PubMed ID: 31136076
[TBL] [Abstract][Full Text] [Related]
38. Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation.
Singh S; Houng A; Reed GL
Circulation; 2017 Mar; 135(11):1011-1020. PubMed ID: 28028005
[TBL] [Abstract][Full Text] [Related]
39. Thyroid dysfunction and fibrin network structure: a mechanism for increased thrombotic risk in hyperthyroid individuals.
Hooper JM; Stuijver DJ; Orme SM; van Zaane B; Hess K; Gerdes VE; Phoenix F; Rice P; Smith KA; Alzahrani SH; Standeven KF; Ajjan RA
J Clin Endocrinol Metab; 2012 May; 97(5):1463-73. PubMed ID: 22378816
[TBL] [Abstract][Full Text] [Related]
40. BβArg448Lys polymorphism is associated with altered fibrin clot structure and fibrinolysis in type 2 diabetes.
Greenhalgh KA; Strachan MW; Alzahrani S; Baxter PD; Standeven KF; Storey RF; Ariens RA; Grant PJ; Price JF; Ajjan RA
Thromb Haemost; 2017 Jan; 117(2):295-302. PubMed ID: 27929198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
